These analyses were part of a multicenter , 52-week , randomized , double-blind , placebo-controlled study assessing the efficacy , safety , and tolerability of subcutaneous omalizumab ( > or = 0.016 mg/kg of IgE [ in international unit per milliliter ] per 4 weeks ) in 525 adults with severe allergic asthma .
